A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
← catalyst calendarNCT07383506 · readout ≤ 1,077 d
Sponsored by Cogent Biosciences, Inc. (industry) · COGT — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
90estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2026 | estimated | When the study began enrolling |
| Primary completion | Jul 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- PIK3CA Mutations
- Advanced Solid Tumors, Adult
- Endometrial Cancer
- HR Positive/HER-2 Negative Breast Cancer
- HER2-low Breast Cancer
Intervention
- Drug: CGT6297
Primary outcomes
what the primary-completion date above is the date OFIncidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Phase 1a]
measured Approximately 12 months
Overall Response Rate [Phase 1b]
measured Approximately 8 months
Permalink · COGT's whole pipeline · Catalyst calendar · Every registered study · What changed